Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Differentiated thyroid cancer (DTC) typically has an excellent prognosis, but some cases become refractory to standard treatments.
• Novel therapeutic strategies targeting specific molecular pathways are needed for refractory DTC.
• Wee1 kinase inhibition with adavosertib presents a potential new approach for cancer therapy.

Purpose of the Study:

• To evaluate the efficacy of adavosertib in preclinical models of differentiated thyroid cancer.
• To investigate the mechanisms of adavosertib action, including cell cycle effects and apoptosis induction.
• To assess the synergistic potential of adavosertib in combination with other targeted therapies.

Main Methods:

• Adavosertib treatment of four human DTC cell lines.
• Cell cycle analysis and apoptosis assays.
• In vivo xenograft studies using DTC tumor models.
• Combination therapy studies with dabrafenib/trametinib and lenvatinib.

Main Results:

• Adavosertib demonstrated dose-dependent growth inhibition and induced G2/M cell cycle arrest and apoptosis in DTC cell lines.
• Sensitivity to adavosertib correlated with baseline Wee1 expression.
• Adavosertib significantly inhibited tumor growth in vivo.
• Combination therapy with adavosertib, dabrafenib, and trametinib showed strong synergism in vitro and robust tumor suppression in vivo in a BRAF-mutant model.
• Combination therapy with adavosertib and lenvatinib was more effective than monotherapy in a follicular thyroid cancer model.

Conclusions:

• Adavosertib exhibits significant preclinical anti-cancer activity against differentiated thyroid cancer.
• Adavosertib demonstrates potential as a therapeutic agent for refractory DTC, particularly in combination regimens.
• Targeting Wee1 with adavosertib represents a promising strategy for advancing DTC treatment options.